Liquid Biopsies: DNA Size Matters
News Jul 19, 2016
The liquid biopsy, a new type of blood test for detecting and monitoring cancer, is a welcome reprieve from typical biopsies. The minimally invasive test could reduce the need for the sometimes painful and risky procedures involved in sampling tumours, particularly those that reside deep within the body. However, thus far, the utility of the test has been limited by its sensitivity, particularly in its detection of solid tumours that have not yet metastasized.
A study led by the University of Utah School of Medicine reports an advance that could directly increase the sensitivity of liquid biopsies. Liquid biopsies work by detecting pieces of DNA from tumours that are shed into the blood. But so-called circulating tumour DNA can be difficult to pick out amidst abundant circulating DNA from healthy cells. Published on July 18 in PLOS Genetics, the study demonstrates that the fragments of circulating tumour and healthy DNA in cancer patients are different sizes, a property that can be exploited to distinguish between the two types of DNA.
“This development has the potential to enable earlier detection of solid tumours through a simple blood draw by substantially improving our ability to detect very low quantities of circulating DNA derived from tumour cells,” says corresponding author and assistant professor of paediatrics Hunter Underhill, M.D., Ph.D. He initiated the research while in the lab of senior author Jay Shendure, M.D., Ph.D., a professor in genome sciences at the University of Washington. Collaborators also include Mary Bronner, M.D., a professor in the department of pathology at the U of U, and at ARUP Laboratories.
The size difference between tumour and healthy circulating DNA was initially discovered in animal tumour models created by creating tumours from human cancer cells. In a model of glioblastoma, a brain cancer that does not metastasize outside of the brain, they could readily see that the length of circulating tumour DNA was smaller than healthy DNA by 20-50 base pairs. This size difference was then confirmed in an animal model of liver cancer indicating the size difference may be present in more than one type of tumour. However, it was unclear at this stage in their research if this was a species-specific finding limited to animal tumour models or if this was a biologic phenomenon that may also be present in cancer patients.
In a following step, the investigators then compared circulating DNA from melanoma patients to that from healthy volunteers. They found that their observations from animal models held true in that the average length of all the DNA pieces present in the blood from melanoma patients was 20-50 base pairs shorter compared to the DNA pieces in blood from healthy volunteers. Upon sequencing the DNA, they found that DNA fragments containing mutated genes – markers of tumours – were typically smaller than healthy versions of the gene from within the same patient. The results suggested that circulating tumour DNA is more likely to be shorter than circulating healthy DNA. Therefore, Underhill explains, selecting for pieces that are smaller in size should enrich for DNA that comes from tumours. If a person carries them, separation of specific DNA fragments based on size should make them easier to see – similar to reducing the size of the haystack without removing or changing the size of the needle.
To test the notion, the scientists examined DNA from four lung cancer patients, isolating fragments that were 20-50 base pairs shorter than the total average size in circulation. Doing so increased the proportion of tumour to healthy DNA by 2.5 to 9-fold. The approach was most successful in making a difference in samples from the two patients in which the smaller-sized tumour DNA was not readily apparent, which may represent patients with low tumour burden and previously difficult to detect circulating tumour DNA. “It’s possible that jump in sensitivity could make the difference between being able to detect a cancer, and not,” says Underhill. Together, the findings support the idea that sorting for smaller DNA fragment size could increase the sensitivity of liquid biopsies for tracking many different types of cancers
“The size difference demonstrated by our study is a critical step in the evolution of circulating tumour DNA testing,” adds Bronner. “We are now developing methods to better extract the circulating tumour DNA, taking advantage of this size difference, to further advance in this exciting new realm of molecular oncology.”
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018